

ADDENDUM

CLINICAL STUDY PROTOCOL

Grupo de Estudo da Doença Inflamatória Intestinal (GEDII)



A study in the real-world practice to evaluate the impact of biosimilar infliximab (**Remsima**) in clinical outcomes in patients with inflammatory bowel diseases: a 2-year longitudinal analysis from the GEDII **Registry**.

Study code: **REMREGISTER**

Type of study: Observational

Study sponsor: Grupo de Estudo da Doença Inflamatória Intestinal (GEDII)

Name of Scientific Coordinator: Prof. Fernando Magro

Inclusion Criteria

In the REMREGISTER Study should be considered as inclusion criteria the following condition:

- Patients already under maintenance treatment with Remsima at time of inclusion in the study.